Key Drivers
- Liquidity cushion
- Cash burn
- Equity erosion
AIAI Summary
KOD has shifted from a long-duration biotech story to a binary December 2026 PEAK readout trade, with the stock already pricing in success while cash only buys runway—not safety—so upside now depends on KSI-101 validating the move and any disappointment could trigger a sharp reset.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity cushion
- •Cash burn
- •Equity erosion
KOD has adequate near-term liquidity, but weakening cash, rising leverage, persistent losses, negative free cash flow, and a stretched book-value valuation make the equity increasingly risky.
Price Behavior
Key Price Behavior Insights:
- •Uptrend breakout
- •Sharp rebound
- •Near-term extension
KOD has trended higher over the last month, broke above prior resistance after a sharp rebound from $39.83, and now looks constructive but slightly extended near $45.40 with $41–$42 support.
Brief drop to $39.83 on 2026-08-03 followed by a sharp multi-day rebound
Sentiment & News
Key News Insights:
- •Trial enrollment
- •Data timeline intact
- •Catalyst mismatch
Kodiak Sciences' shares jumped without a clear same-day catalyst, while the later Phase 3 PEAK enrollment completion provided the real positive driver by keeping the December 2026 data readout on schedule.
The update is modestly positive for KOD as it confirms steady clinical execution, but it does not materially change near-term valuation until topline data arrives
Similar Companies in Healthcare
Other companies in the same sector with AI ratings